[{"id":"c4d024fe-0ad9-4ccb-bdd3-007d1646b965","acronym":"GIM21","url":"https://clinicaltrials.gov/study/NCT05735392","created_at":"2023-02-21T16:01:47.579Z","updated_at":"2024-07-02T16:35:55.179Z","phase":"","brief_title":"Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial)","source_id_and_acronym":"NCT05735392 - GIM21","lead_sponsor":"Consorzio Oncotech","biomarkers":" EGFR • HER-2 • PIK3CA • PTEN • AKT1 • PIK3R1 • MUC4","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • PIK3CA mutation • HER-2 mutation • PIK3R1 mutation","tags":["EGFR • HER-2 • PIK3CA • PTEN • AKT1 • PIK3R1 • MUC4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • PIK3CA mutation • HER-2 mutation • PIK3R1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 11/07/2018","start_date":" 11/07/2018","primary_txt":" Primary completion: 01/12/2022","primary_completion_date":" 01/12/2022","study_txt":" Completion: 01/12/2022","study_completion_date":" 01/12/2022","last_update_posted":"2023-02-20"},{"id":"b110f80b-787e-41a9-a974-9daad82f715d","acronym":"CaPaLong","url":"https://clinicaltrials.gov/study/NCT04436679","created_at":"2021-04-24T00:52:57.081Z","updated_at":"2024-07-02T16:36:10.061Z","phase":"","brief_title":"INTER-Regional COHORTE of Long Term Pancreatic Cancer Survivors","source_id_and_acronym":"NCT04436679 - CaPaLong","lead_sponsor":"University Hospital, Lille","biomarkers":" MSLN • MUC16 • MUC4 • MUC5AC","pipe":" | ","alterations":" MUC4 expression • MUC5AC expression","tags":["MSLN • MUC16 • MUC4 • MUC5AC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC4 expression • MUC5AC expression"],"overall_status":"Recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 02/02/2021","start_date":" 02/02/2021","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2022-05-23"},{"id":"0f922648-2605-4a12-9b33-08b5a5febdbe","acronym":"","url":"https://clinicaltrials.gov/study/NCT02146313","created_at":"2021-01-18T09:58:27.690Z","updated_at":"2024-07-02T16:37:09.655Z","phase":"Phase 1","brief_title":"A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer","source_id_and_acronym":"NCT02146313","lead_sponsor":"Genentech, Inc.","biomarkers":" MUC16 • MUC4","pipe":" | ","alterations":" MUC16 expression","tags":["MUC16 • MUC4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RG7882"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 06/22/2014","start_date":" 06/22/2014","primary_txt":" Primary completion: 06/18/2018","primary_completion_date":" 06/18/2018","study_txt":" Completion: 06/18/2018","study_completion_date":" 06/18/2018","last_update_posted":"2018-06-21"}]